Eupraxia Pharmaceuticals Inc
EPRX.CA
$
Closing
1D
YTD
EPRX
BBG00Z83VS56
Market cap
$
52 week high
$
52 week low
$
Volume
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$
Analysts' Rating
STRONG BUY
Price Target (Mean)
9.01
Total Analysts
1
P/E
Operating Margin
0%
Beta
Revenue Growth
0%
52 week high
$
52 week low
$
Div. Yield
%
EPS Growth
-17.9
Company Profile
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
